NCT02665065Phase 3Active not recruiting

Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia

Study sponsor: Actinium Pharmaceuticals

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2022-06Actual
Enrollment · participants153Actual
Source updated2023-07-19Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview